CL2018000142A1 - Métodos para el tratamiento de trastornos de desarrollo con gaboxadol. - Google Patents

Métodos para el tratamiento de trastornos de desarrollo con gaboxadol.

Info

Publication number
CL2018000142A1
CL2018000142A1 CL2018000142A CL2018000142A CL2018000142A1 CL 2018000142 A1 CL2018000142 A1 CL 2018000142A1 CL 2018000142 A CL2018000142 A CL 2018000142A CL 2018000142 A CL2018000142 A CL 2018000142A CL 2018000142 A1 CL2018000142 A1 CL 2018000142A1
Authority
CL
Chile
Prior art keywords
gaboxadol
treatment
syndrome
developmental disorders
methods
Prior art date
Application number
CL2018000142A
Other languages
English (en)
Spanish (es)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CL2018000142A1 publication Critical patent/CL2018000142A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2018000142A 2015-07-17 2018-01-17 Métodos para el tratamiento de trastornos de desarrollo con gaboxadol. CL2018000142A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562193717P 2015-07-17 2015-07-17
US201562207595P 2015-08-20 2015-08-20
US201662332567P 2016-05-06 2016-05-06
US201662346763P 2016-06-07 2016-06-07
US15/209,862 US20170014393A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol

Publications (1)

Publication Number Publication Date
CL2018000142A1 true CL2018000142A1 (es) 2018-07-13

Family

ID=57774846

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000142A CL2018000142A1 (es) 2015-07-17 2018-01-17 Métodos para el tratamiento de trastornos de desarrollo con gaboxadol.

Country Status (17)

Country Link
US (8) US20170014393A1 (enExample)
EP (2) EP4541420A3 (enExample)
JP (3) JP2018520189A (enExample)
KR (2) KR20180031721A (enExample)
CN (2) CN108024997A (enExample)
AU (2) AU2016295138B2 (enExample)
BR (1) BR112018000933A2 (enExample)
CA (1) CA2992734A1 (enExample)
CL (1) CL2018000142A1 (enExample)
CO (1) CO2018000375A2 (enExample)
ES (1) ES3021189T3 (enExample)
HK (1) HK1250951A1 (enExample)
IL (2) IL256912B2 (enExample)
MX (2) MX391708B (enExample)
PE (2) PE20190338A1 (enExample)
TW (2) TW202325293A (enExample)
WO (1) WO2017015049A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3372229T (pt) * 2014-06-06 2021-06-17 Ovid Therapeutics Inc Métodos para aumentar a inibição tónica e tratar a síndrome de angelman
HK1250951A1 (zh) 2015-07-17 2019-01-18 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
WO2018098111A1 (en) * 2016-11-22 2018-05-31 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
CN111432814B (zh) * 2017-11-14 2024-05-14 爱思开生物制药株式会社 用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途
CN112739353A (zh) * 2018-06-14 2021-04-30 奥维德医疗公司 Mir-92a或mir-145在治疗安格曼综合征中的用途
MX2021002113A (es) * 2018-08-22 2021-06-23 Ovid Therapeutics Inc Uso de gaboxadol en el tratamiento de trastornos del tracto gastrointestinal y asma.
KR20210062662A (ko) * 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
WO2020106976A1 (en) * 2018-11-21 2020-05-28 Certego Therapeutics Combination of gaboxadol and lithium for the treatment of psychiatric disorders
EP3883566A4 (en) 2018-11-21 2022-09-07 Certego Therapeutics Inc. GABOXADOL FOR REDUCE RISK OF SUICIDE AND RAPID RELIEF OF DEPRESSION
AU2019405489A1 (en) 2018-12-17 2021-06-10 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
CN114340597B (zh) * 2019-06-07 2025-01-28 帕克斯医学有限公司 用于治疗中枢神经系统障碍的组合物和方法
MX2022000663A (es) * 2019-07-15 2022-02-16 Ovid Therapeutics Inc Formulaciones farmaceuticas que contienen gaboxadol para tratamiento terapeutico.
EP4051272A4 (en) * 2019-12-18 2023-01-04 Ovid Therapeutics Inc. GABOXADOL FOR THE THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
CA3182508A1 (en) 2020-05-20 2021-11-25 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
DE60142632D1 (de) * 2000-11-30 2010-09-02 Novodermix Internat Ltd Heilung von wunden
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
MEP6308A (xx) 2001-05-21 2010-02-10 Lundbeck & Co As H Granulirani preparati gaboksadola
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
ATE459353T1 (de) 2003-06-25 2010-03-15 Lundbeck & Co As H Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
WO2005063248A1 (en) 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
CN1942185A (zh) * 2004-04-02 2007-04-04 H.隆德贝克有限公司 用加波沙朵治疗呼吸功能损伤
JP2007530604A (ja) * 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
WO2007053596A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
CA2670116C (en) * 2006-11-22 2015-03-10 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
US20090269795A1 (en) 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
CA2732636A1 (en) * 2008-09-01 2009-05-07 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of pat1 or oat
US20100286762A1 (en) 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
CN102147667A (zh) 2010-02-08 2011-08-10 深圳富泰宏精密工业有限公司 触控笔
US9089531B2 (en) 2010-09-28 2015-07-28 The Regents Of The University Of California GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
WO2012075286A2 (en) 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
US9480695B2 (en) 2011-09-29 2016-11-01 The University Of Tokyo Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder
US20140371210A1 (en) 2011-10-13 2014-12-18 Jaleva Pharmaceuticals, Llc Methods and compositions for rapid transbuccal delivery of active agents
EP4335505A3 (en) * 2012-11-30 2024-06-05 The Regents of The University of California Anticonvulsant activity of steroids
US20150313913A1 (en) 2013-02-05 2015-11-05 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
PT3372229T (pt) * 2014-06-06 2021-06-17 Ovid Therapeutics Inc Métodos para aumentar a inibição tónica e tratar a síndrome de angelman
US9802945B2 (en) 2014-06-12 2017-10-31 Pfizer Limited Imidazopyridazine derivatives as modulators of the GABAA receptor activity
HK1250951A1 (zh) 2015-07-17 2019-01-18 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
CA2994952A1 (en) 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
ES2936400T3 (es) 2015-10-22 2023-03-16 Cavion Inc Métodos para tratar el síndrome Angelman
JP2019517469A (ja) 2016-05-26 2019-06-24 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ピプラドロールを用いる行動症候群の治療方法
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
WO2018098111A1 (en) 2016-11-22 2018-05-31 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus

Also Published As

Publication number Publication date
HK1250951A1 (zh) 2019-01-18
ES3021189T3 (en) 2025-05-26
US20230071127A1 (en) 2023-03-09
JP2023103375A (ja) 2023-07-26
IL256912A (en) 2018-03-29
AU2021250862B2 (en) 2023-11-09
EP3324961B1 (en) 2025-03-19
US20210030727A1 (en) 2021-02-04
AU2021250862A1 (en) 2021-11-04
AU2016295138A1 (en) 2018-02-08
EP4541420A3 (en) 2025-06-25
CO2018000375A2 (es) 2018-04-19
CN108024997A (zh) 2018-05-11
EP3324961C0 (en) 2025-03-19
TWI819995B (zh) 2023-11-01
KR20180031721A (ko) 2018-03-28
IL305342A (en) 2023-10-01
US12465597B2 (en) 2025-11-11
CN116531370A (zh) 2023-08-04
US11096929B2 (en) 2021-08-24
MX2018000745A (es) 2018-08-15
PE20190338A1 (es) 2019-03-07
PE20230735A1 (es) 2023-05-03
MX391708B (es) 2025-03-21
EP3324961A4 (en) 2019-03-13
BR112018000933A2 (en) 2018-09-04
CA2992734A1 (en) 2017-01-26
TW202325293A (zh) 2023-07-01
TW201707700A (zh) 2017-03-01
IL256912B1 (en) 2023-09-01
EP3324961A1 (en) 2018-05-30
US20190117632A1 (en) 2019-04-25
MX2022004734A (es) 2022-05-13
JP2018520189A (ja) 2018-07-26
AU2016295138B2 (en) 2021-11-04
WO2017015049A1 (en) 2017-01-26
IL256912B2 (en) 2024-01-01
US20190255027A1 (en) 2019-08-22
US20180338960A1 (en) 2018-11-29
JP2021130687A (ja) 2021-09-09
US20190321342A1 (en) 2019-10-24
US20180098974A1 (en) 2018-04-12
US20170014393A1 (en) 2017-01-19
EP4541420A2 (en) 2025-04-23
KR20240160666A (ko) 2024-11-11

Similar Documents

Publication Publication Date Title
CL2018000142A1 (es) Métodos para el tratamiento de trastornos de desarrollo con gaboxadol.
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
UY36275A (es) Compuestos aminopirimidinilo
GT201400230A (es) Necleòsidos de espìrooxetano de uracilo
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
ECSP18003372A (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2015000787A1 (es) Derivados de 1,2,4-triazina para el tratamiento de infecciones virales.
ECSP17054980A (es) Inhibidores selectivos de bace1
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2016002940A1 (es) Derivado de carotenoides, sal farmacéuticamente aceptable del mismo, o éster o amida farmacéuticamente aceptables del mismo
CU20160169A7 (es) Compuestos y composiciones para inducir condrogénesis
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
CO2019008110A2 (es) Activador de nrf2
CL2016000939A1 (es) Compuestos derivados de pirimidina con actividad inhibidora de syk uso en el tratamiento de una condición inmune, enfermedades inflamatorias, trastornos alérgicos, lupus eritomatosos, epoc, bronquitis, rinitis alérgica, asma, entre otras composición farmacéutica que los comprende.
CL2019000487A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana.
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas
AR095015A1 (es) Compuestos de azetidiniloxifenilpirrolidina
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
AR084051A1 (es) Derivados de 1-hidroxi-2-oxo-hidroquinolina, composiciones farmaceuticas que los contienen y uso de los mismos para tratar deficits cognitivos asociados con esquizofrenia y otros trastornos psiquiatricos y/o neurologicos
FR3027522B1 (fr) Composition poreuse chargee en principe actif
MX363558B (es) Composiciones farmaceuticas que comprenden flurbiprofeno.
CR20160146A (es) Derivados de urea indol sustituido con glucopiranosil y su uso como inhibidores sglt